AstraZeneca plc (LON:AZN) received a GBX 4,550 ($59.84) target price from research analysts at UBS AG in a note issued to investors on Thursday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. UBS AG’s price target indicates a potential downside of 6.57% from the company’s current price.
A number of other analysts also recently weighed in on AZN. Jefferies Group LLC cut their price target on shares of AstraZeneca plc from GBX 5,500 ($72.34) to GBX 5,300 ($69.71) and set a “hold” rating on the stock in a research report on Wednesday, July 12th. Citigroup Inc. reiterated a “buy” rating and issued a GBX 6,000 ($78.92) price target on shares of AstraZeneca plc in a research report on Thursday, July 13th. Liberum Capital reiterated a “buy” rating and issued a GBX 5,500 ($72.34) price target on shares of AstraZeneca plc in a research report on Thursday, July 13th. Kepler Capital Markets restated a “buy” rating and set a GBX 5,500 ($72.34) target price on shares of AstraZeneca plc in a report on Thursday, July 13th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a report on Thursday, July 13th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 5,247.18 ($69.01).
Shares of AstraZeneca plc (LON:AZN) traded down GBX 92 ($1.21) during trading hours on Thursday, hitting GBX 4,870 ($64.05). 3,189,397 shares of the company were exchanged, compared to its average volume of 1,940,000. AstraZeneca plc has a 1-year low of GBX 3,996 ($52.56) and a 1-year high of GBX 5,520 ($72.60).
TRADEMARK VIOLATION WARNING: “AstraZeneca plc (AZN) PT Set at GBX 4,550 by UBS AG” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/11/astrazeneca-plc-azn-pt-set-at-gbx-4550-by-ubs-ag.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.